Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Why Novo Nordisk Stock Popped After Earnings
11:42am, Wednesday, 07'th May 2025
GLP-1 drugmaker Novo Nordisk's (NVO 2.01%) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
11:30am, Wednesday, 07'th May 2025
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
11:29am, Wednesday, 07'th May 2025
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with dilute
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat
10:30am, Wednesday, 07'th May 2025
Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI)
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
10:24am, Wednesday, 07'th May 2025
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Novo Nordisk investors relieved after expected guidance cut
09:02am, Wednesday, 07'th May 2025
Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
09:01am, Wednesday, 07'th May 2025
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due what Novo says is illegal compounding of GLP-1 medicines.
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
07:21am, Wednesday, 07'th May 2025
Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
06:26am, Wednesday, 07'th May 2025
U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.
Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
05:53am, Wednesday, 07'th May 2025
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country w
Novo Nordisk CEO says 'compounders took a part of our business away'
05:44am, Wednesday, 07'th May 2025
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Drugmaker Novo Nordisk drops gender representation requirements in the US
05:22am, Wednesday, 07'th May 2025
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity a
Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.
03:59am, Wednesday, 07'th May 2025
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.
Novo Nordisk shares rise despite cut to 2025 outlook
03:19am, Wednesday, 07'th May 2025
Investors breathed a sigh of relief on Wednesday as shares in Novo Nordisk (NYSE:NVO) rose 3% in early trading, despite the drugmaker trimming its sales and profit forecasts for 2025. The downgrade, w
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
02:13am, Wednesday, 07'th May 2025
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.
